Publications en collaboration avec des chercheurs de Hospital Clínico San Carlos de Madrid (16)

2021

  1. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer

    Biomedicine and Pharmacotherapy, Vol. 144

2019

  1. UNR/CSDE1 expression is critical to maintain invasive phenotype of colorectal cancer through regulation of c-MYC and epithelial-to-mesenchymal transition

    Journal of Clinical Medicine, Vol. 8, Núm. 4

2018

  1. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

  2. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept

    PLoS ONE, Vol. 12, Núm. 8

2016

  1. Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy

    Pathology Research and Practice, Vol. 212, Núm. 12, pp. 1133-1137

  2. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer

    Journal of Cellular and Molecular Medicine, Vol. 20, Núm. 9, pp. 1729-1736

  3. PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma

    Pathology and Oncology Research, Vol. 22, Núm. 2, pp. 377-383

  4. Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: A retrospective observational cohort study

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. Identification of Poor-outcome Biliopancreatic Carcinoma Patients with Two-marker Signature Based on ATF6α and p-p38 "sTARD Compliant"

    Medicine (United States), Vol. 94, Núm. 45, pp. e1972

2014

  1. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

    BMC Cancer, Vol. 14, Núm. 1

2012

  1. Guidelines for biomarker testing in colorectal carcinoma (CRC): A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 726-739

  2. Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon

    Revista Espanola de Patologia

  3. Recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

    Revista Espanola de Patologia

2011

  1. Treatment recommendations for metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178

2001

  1. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis

    Human Molecular Genetics, Vol. 10, Núm. 26, pp. 3001-3007